The EWS-Fli1 fusion gene, resulting from a t(11;22) translocation, plays a key role in the Ewing's sarcoma pathogenesis. In the past, a 25mer phosphorothioate antisense oligodeoxynucleotide, a structured 30mer phosphorothioate/phosphodiester antisense oligodeoxynucleotide, and an antisense siRNA, delivered either free, by vectors or intracellularly expressed, were found potent in various in vitro and in vivo Ewing sarcoma models. Because of differences among the models used in the literature, the comparison of various antisense agents with each other is difficult. Therefore, we aimed to evaluate these three antisense agents in NIH/3T3 fibroblasts which stably express the human EWS-Fli1 oncogene as an in vitro model of Ewing sarcoma. Fours parameters were considered including oncogene EWS-Fli1 and EWS mRNA expression, cellular proliferation, and actin cytoskeleton organization. They illustrate the antisense efficacy, the specificity and the phenotypic reversion for the last two ones, respectively. We showed that the structured 30mer phosphorothioate/phosphodiester antisense oligodeoxynucleotide and antisense siRNA represent the best choice for clinical trials. Nevertheless, the antisense ODN is more specific than the siRNA and represents the most efficient antisense agent. Its activity may be improved after the selection of an appropriate delivery vector which is able to increase cell penetration and to protect it from nucleases degradation.
INTRODUCTION
The Ewing sarcoma family of tumours (ESFT) is the second most common malignant neoplasm of bone among children and adolescents. ESFT comprises tumours which are characterised by specific translocations involving the EWS gene and one of several members of the ETS family of transcription factors. This family includes a great number of oncogenic transcription factors involved in the regulation of tumor and developmental processes. In 90-95% of the cases, the translocation t(11;22)(q24;12) creates the EWS-Fli1 fusion gene. This results in the expression of a chimerical oncoprotein consisting of the N-terminal domain of ews and the DNA-binding domain of fli1. Depending on the locations of the EWS and Fli1 genomic breakpoints, several types of EWS-Fli1 fusion gene exist. The fusion of EWS exon 7 to Fli1 exon 6 (type 1) is the most common (60% of cases). The ews-fli1 oncoprotein acts as an aberrant transcription factor. Because it modulates the expression of various target genes, ews-fli1 is considered as the main cause of Ewing sarcoma [1] [2] [3] .
A new therapeutic strategy against Ewing sarcoma would be to block specifically the expression of the ews-fli1 oncoprotein. Therefore, we focus on the very powerful antisense tools which specifically inhibit gene expression at RNA level and then block the encoded protein synthesis: short frag-ments of single-stranded DNA called antisense oligodeoxynucleotides (AS ODNs) and small interfering RNAs (siRNAs). The use of such technology was early studied on Ewing sarcoma models [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . We will consider either AS ODNs or siRNAs all directed against the type 1 junction breakpoint of human EWS-Fli1 mRNA. Tanaka et al. were the first to use AS ODN with phosphorothioate (PS) linkages. In the micro molar range and without transfection agent, a 25mer PS AS ODN was enough efficient to inhibit the growth of SK-N-MC cells in culture [6] . In a mouse xenograft model of human EWS-Fli1 transformed NIH/3T3 cells, Lambert et al. enclosed the same 25mer PS AS ODN in biocompatible polymeric nanocapsules and observed 70% inhibition of tumour growth after intratumoural injection at a cumulative dose of 5 mg/kg [7] . Maksimenko et al. developed a structured 30mer AS ODN composed by 22 phosphodiester (PO) nucleotides and 8 PS nucleotides. Its internal structure allows protection against nuclease degradation with the advantage of a low number of thioate groups. The excess of thioate groups is well known to induce nonspecific effects and may be responsible for toxicity. When the structured 30mer PS/PO AS ODN was delivered intratumourally by nanocapsules or by chitosan nanospheres (cumulative dose of 4 and 5 mg/kg respectively), they obtained 82% and 66% inhibition of EWS-Fli1 tumour growth in nude mice [10, 11] . At 200 nM, the structured 30mer PS/PO AS ODN bound to chitosan nanospheres or to cationic lipids inhibited both EWS-Fli1 mRNA and protein expression by 50%, in NIH/3T3 permanently expressing human EWS-Fli1 cells culture. Only with cationic lipids, the authors observed also a 50% inhibition of EWS-Fli1 NIH/3T3 cells growth in vitro. On the other hand, the growth inhibition of xenografted EWS-Fli1 NIH/3T3 tumours was noted after intratumoural or intravenous injection of structured 30mer PS/PO AS ODN bound to chitosan nanospheres [14] . Finally, according to Dohjima et al., one AS siRNA intracellularly expressed involved 81% reduction of EWS-Fli1 mRNA expression and 50% Ewing sarcoma cell line TC135 growth inhibition [9] . In a mouse xenograft model of human EWSFli1 transformed NIH/3T3 cells, this AS siRNA enclosed in biocompatible polymeric nanocapsules were found to trigger a dose-dependant inhibition of tumour growth after intratumoural injection (43% and 80% inhibition at 0.8 mg/kg and 1.11 mg/kg, respectively). These results were linked to an inhibition of EWS-Fli1 gene expression [16] .
Each of these three-presented antisense agents (25mer PS AS ODN, structured 30mer PS/PO AS ODN, AS siRNA) constitutes prospects of an efficient Ewing sarcoma treatment. Unfortunately, the experimental conditions are extremely different from a study to another. So, it is difficult to compare the antisense agents with each other. In order to select the most efficient, we compared them in the same cell culture conditions after vectorisation by cationic lipids. First, using an in vitro model of Ewing sarcoma (NIH/3T3 stably expressing human EWS-Fli1 oncogene), we determined their antisense efficacy via their ability to inhibit the oncogene expression. Second, as EWS-Fli1 fusion gene consists of the first seven exons of EWS joined to Fli1 from its exon 6, we controlled the specificity of antisense agents by checking if the EWS gene expression is modified in human EWS-Fli1 transformed murine fibroblasts and parental NIH/3T3 cells. Indeed, EWS has been shown to act as an adaptor molecule linking gene transcription and mRNA processing by interacting with RNA polymerase II and the splicing factors. Consequently, the modification of its physiological expression in normal cells may have undesirable effect [17] [18] [19] . Third, the human EWS-Fli1 expression into NIH/3T3 cells increases their growing rate in comparison with the untransformed NIH/3T3 cells. We evaluated the effect of these three antisense agents on the cell proliferation. Fourth, common features including disruption of actin filaments are noticed after transformation of cells by various oncogenes. These changes in microfilament structure are highly related to both anchorage-independent growth and cellular tumourigenicity, suggesting fundamental roles for actin filaments in oncogenic transformation [20] . In this way, NIH/3T3 fibroblasts feature a highly organised actin filament network whereas tumour EWS-Fli1 NIH/3T3 cells exhibit a complete disruption of their actin cytoskeleton [21] . So, we evaluated the different antisense agents according to their ability to restore actin fibres network.
The aim of this work was to compare the efficiency of three different antisense agents described in the literature on their ability to block specifically EWS-Fli1 expression and the phenotypes associated to the cellular transformation. Finally, we are capable of selecting a good candidate to design a new therapy for patients with Ewing sarcoma.
MATERIALS AND METHODS

Cell Lines
As a model of Ewing sarcoma, we used the fibroblastic NIH/3T3 cell line stably transfected with the human EWSFli1 junction oncogene which was a generous gift from Dr J. Ghysdael (Institut Curie; Orsay, France). The cells were grown in DMEM containing glucose (4500 mg/L) and glutamax I (GIBCO; Cergy-Pontoise, France), supplemented by penicillin (100 U/mL; GIBCO), streptomycin (100 g/mL; GIBCO), 10% heat-inactivated new born bovine serum (GIBCO), and puromycin (2.5 g/mL; Sigma; Lyon, France) at 37 °C in a 5% CO 2 water-saturated atmosphere. As a negative control, NIH/3T3 cell line was maintained under the same conditions without puromycin. The parental NIH/3T3 fibroblasts only express the EWS gene whereas the tumour EWS-Fli1 NIH/3T3 cells express both the EWS and the EWS-Fli1 genes.
Antisense Oligodeoxynucleotides (AS ODNs) and Small Interfering RNA (siRNAs)
The oligodeoxynucleotides, Fig. (1) , directed against the breakpoint of the type 1 human EWS-Fli1 fusion gene were synthesized and purified by Eurogentec (Seraing, Belgium). The first one is a 25mer fully constituted by phosphorothioate linkages (which are noted by*) with the following sequence: 5'-G*A*C*T*G*A*G*T*C*A*T*A*A*G* A*A*G*G*G*T*T*C*T*G*C-3' (25mer PS AS ODN) [6] . The second one presents a stem loop structure in charge of protecting them from nuclease degradation with a low number of chemically modified bases to decrease the unspecific effects. This ODN contains a 22 phosphodiesters stem and a 8 phosphorothioates loop: 5'-GTAGCGAAGGGT*T*C*T* G*C*T*G*CCCGTAGCTGC-3' (structured 30mer PS/PO AS ODN; application for a patent Bioalliance Pharma S.A., CNRS, IGR, No 99/02921, 09/03/1999) [11] . As the two ODNs are directed against the junction breakpoint of EWS- Fli1, they have 12 common bases. The 25mer is much more targeted to the Fli1 part of the fusion gene sequence whereas the 30mer is much more targeted to the EWS part. We also used an AS ODN fully constituted by phosphodiester linkages, which has the same sequence than the structured 30mer PS/PO AS-ODN but contains methyl modification at the 2' position of riboses present in the loop structure (structured 30mer 2'OMe PO AS ODN). The following ODNs were utilised as controls (CTL): 5'-G*C*A*G*A*A*C*C*C*T* T*C*T*T*A*T*G*A*C*T*C*A*G*T*C*-3' (25mer PS CTL ODN), and 5'-CTCACCTTACTT*A*T*C*A*C*A*T* CATCTCCTCAT-3' (30mer PS/PO CTL ODN).
The sequences of the siRNA directed against the oncogene, Fig. (1) , are as follows: 5'-GGGUUCUGCUGCCCG UAGC-d(UG)-3' (antisense strand AS siRNA), 5'-GCUACG GGCAGCAGAACCC-d(UU)-3' (sense strand AS siRNA) [9] . The control siRNA contains four mismatched bases (underlined):
5'-GGCUUGUGCUGUCCGCAGC-d(UG)-3' (antisense strand CTL siRNA), 5'-GCUGCGGACAGCA CAAGCC-d(UU)-3' (sense strand CTL siRNA). Duplexes formation was performed by heating equimolar quantities of each strand for 2 minutes at 90 °C, then 1-hour incubation at 37 °C in 100 mM HEPES pH 7.4, 100 mM NaCl buffer.
Transfection Conditions
One day after seeding in 24-well or 6-well plates, EWSFli1 NIH/3T3 or NIH/3T3 cells were transfected with a mixture of ODN (200 nM) or siRNA (50 nM) and Cytofectin TM (ratio 1:2 w:w; GTS; San Diego, USA). Nucleic acid and transfection agent were both diluted in polystyrene tubes (Receptor Technologies; Oxon, England) containing 10 mM HEPES pH 7.4, 100 mM NaCl buffer. The transfection volume was 1:10 of the final cell culture volume. The transfection mix was incubated 15 minutes at ambient temperature to make sure that the complexes were well established before adding to the cell culture medium. The cells were then incubated for 4 hours before analysis or the medium was replaced by a fresh one for a further incubation.
Quantification of EWS-Fli1 and EWS mRNA Expressions by Real Time Q-PCR
Cultured cells were transfected in 6-wells plates. After 4 hours treatment, the cells medium was discarded and 200 L of lysis buffer (4 M guanidium thiocyanate, 25 mM Na citrate pH 7, 0.5% sarcosyl and 0.1 M -mercaptoethanol) were added into each well. The lysate of 3 wells was pooled and total RNA was phenol extracted as follows. 40 L of 2 M Na acetate pH 4, 400 L of water saturated phenol and 120 L of chlorophorm:isoamyl alcohol (49:1, v:v) were added. The mixture was centrifugated at 13000 rpm for 15 minutes. 200 L of isopropanol were mixed with 200 L of the supernatant and incubated at -20 °C for 1 hour to salt out total RNA. Then, total RNA was precipitated after centrifugation at 13000 rpm, 4 °C, for 15 minutes. The pellet was washed with cold 75% ethanol and centrifugated once more, at 13000 rpm, 4 °C, for 5 minutes. After drying, the pellet was reconstituted in 10 L of distilled water which contained RNasin (1 U/ L; Promega, Mannheim, Allemagne). Concentration of RNA preparation was evaluated by OD 260 nm absorption and for quality by agarose gel electrophoresis followed by ethidium bromide staining. The cDNA was synthesized from 2 g total RNA in a 20 L reaction volume using oligo(dT) (Promega) and reverse transcriptase M-MLV (Moloney Murine Leukemia Virus, Promega) for 1 hour at 42 °C according to the manufacturer's instructions.
Then, the expressions of the EWS gene and the EWSFli1 oncogene were measured by real-time quantitative PCR using SYBR ® Green I Dye (Applied Biosystems; Foster City, USA). Two sets of primers were used to study both EWS (forward 5'-AGCAGTTACTCTCAGCAGAACACC-3', backward 5'-TCCACCAGGCTTATTGAAGCCACC-3') and EWS/Fli1 (forward 5'-AGCAGTTACTCTCAGCAGA ACACC-3', backward 5'-CCAGGATCTGATACGGATCT GGCTG-3') gene expression. PCR amplifications were performed according to Gene Amp ® 5700, RNA Sybr ® Green PCR protocol (Applied Biosystems) with 0.17 pmol and 0.34 pmol of backward and forward primers, respectively and a serial dilution of standard cDNA (0.01-100 nmol) in a 25 μl final reaction volume. Thermocycling was conducted using ABI System Prism ® 7000 Sequence Detection System initiated by 15 minutes incubation at 94°C and followed by 40 cycles (95°C, 15 seconds; 60°C, 60 seconds) with a single fluorescent reading taken at the end of each cycle. Ct values were determined by the ABI Prism ® 7000 Sequence Detection System software. Standard curves were made to quantify the level of gene expression. PCR amplification was run for samples in duplicate and the representative results were expressed as the relative expression quantities of targets compared to those of untreated control that were normalised with the internal control 18s.
Proliferation Assay
After 24 hours treatment with antisense agent in 24-wells dishes, cellular proliferation was determined by MTT assay which measures the mitochondrial deshydrogenase succinate activity. After the medium replacement, a 0.5 mg/mL MTT (Sigma) solution was added, and the cells were incubated at 37 °C for 2 hours. The cells were lysed overnight at 37 °C with the solution of 5% SDS in 5 mM HCl. Then, the OD of the supernatant was measured at the 570 nm/630 nm wavelengths ratio with an automatic MRX II plate reader (Dynex Technologies; Chantilly, USA).
Western-Blot Analysis
After 24 hours treatment with structured 30mer PS/PO AS ODN in 6-wells dishes, ews-fli1 and ews protein expressions were measured by western-blot analysis according to standard procedures. Briefly, proteins were harvested in 100 l lysis buffer (RIPA solution) containing Tris 50 mM, NaCl 150 mM, EDTA 1 mM glycerol 10%, NP 40 0.5% and complete protease inhibitor (Roche, Germany) at 0 °C for 10 min. Then cell lysate were clarified by centrifugation for 10 min at 12000 g and conserved at -80 °C. Proteins concentrations were determined using BCA protein assay (Pierce). Proteins were separated on 4-10% PAGE (Invitrogen) and transferred on BAF-83 nitro cellulose (Schleicher & Schuell). Proteins were detected with specific anti EWS antibody (generous gift from Dr U. Kovar, Austria). Protein detection was performed by chemioluminescence (ECL, Amersham).
Fluorescent Staining
Cells were seeded onto glass slides and maintained for 24 hours. Then, a transfection was performed daily for 3 days (like previously described). 24h latter, cells were fixed for 20 minutes at 4 °C with PBS containing 4% formaldehyde. The formaldehyde solution was neutralised with 50 mM NH 4 Cl. Disruption of cell membranes cells was carried out for 5 minutes with 0.4% Triton X-100 in PBS. The cells were incubated for 30 minutes with RNase A (10 g/mL in PBS), and then for 20 minutes, at room temperature with 600 nM DAPI (Sigma) and 1 M phalloidin-FITC (Sigma). Glass slides were mounted under Mowiol solution (Calbiochem; San Diego, USA) and observed through a fluorescence microscope (Zeiss; Le Pecq, France).
Statistical Analysis
For the proliferation assay, the percentage of cellular viability was calculated as the average of two independent experiments, and each one was made at least in triplicate (n 12). GraphPad InStat software (San Diego, USA) was used to analyse the data. A two-tailed unpaired t-test was applied to compare the statistical significance of the differences between two groups. P values < 0.001 were considered statistically extremely significant.
RESULTS
Efficacy of the Antisense Agents: The EWS-Fli1 Oncogene Expression
We compared the different antisense agents, after a transfection of 4 hours, according to their ability to inhibit the expression of the human EWS-Fli1 oncogene which is expressed by transformed NIH/3T3 fibroblasts, Fig. (2) . No specific variation in EWS-Fli1 oncogene expression was observed after the treatment of EWS-Fli1 NIH/3T3 cells by the 25mer PS AS ODN or its control sequence (63% and 72% of untransfected cells, respectively). On the contrary, there was a significant difference between the structured 30mer PS/PO AS ODN and the 30mer PS/PO CTL ODN. The level of EWS-Fli1 mRNA expression was respectively reduced to 12% and 55% in comparison with the untreated EWS-Fli1 NIH/3T3 cells. To determine if the sequence of the structured ODN participates totally in the antisense effect or if the loop is mainly responsible, we replaced the RNase H sensitive phosphorothioate bases of the loop by RNase H resistant 2'-O-methyl modified oligodeoxynucleotides. The structured 30mer 2'OMe PO AS ODN inhibited the EWSFli1 mRNA expression as strongly as the unmodified ODN (13% of EWS-Fli1 mRNA in untreated cells). The EWS-Fli1 mRNA expression was also specifically inhibited after transfection with AS siRNA (23% of untransfected cells), whereas it was increased with CTL siRNA (360% of untreated cells). We can notice that structured 30mer PS/PO AS ODN and AS siRNA were capable of silencing EWSFli1 gene expression to a similar level.
Specificity of the Antisense Agents: The EWS Gene Expression
Even if the three studied antisense agents are all directed against the junction of the oncogene, their target sequences are quite different, Fig. (1) . The 25mer PS AS ODN presents a stronger hybridisation to the Fli1 part of EWS-Fli1 whereas structured 30mer PS/PO AS ODN and AS siRNA present stronger hybridisation to the EWS part of EWS-Fli1. To measure the specificity of the antisense agents, we analysed the EWS gene expression after the transfection in NIH/3T3 and EWS-Fli1 NIH/3T3 for 4 hours, Fig. (3) . The 25mer PS CTL ODN did not modify the EWS mRNA expression in the two cell lines (close to 100% in comparison with untreated cells). On the contrary, after transfection with 30mer PS/PO CTL ODN or CTL siRNA, the EWS mRNA level was two-fold increased in EWS-Fli1 NIH/3T3 (202% and 204% of untransfected cells, respectively) and about 1.5 fold increased in NIH/3T3 (154% and 167% compared to untreated cells). With the 25mer PS AS ODN, we observed again a slightly stimulation of the EWS expression in EWSFli1 NIH/3T3 cells (142% of the untransfected cells), whereas it was unmodified in NIH/3T3 (94% in comparison with the untreated cells). In contrast, we noticed cell typedependent inhibitions of the EWS mRNA expression after transfection with structured 30mer PS/PO AS ODN or AS siRNA, Table 1 . When EWS-Fli1 NIH/3T3 cells were transfected with the structured 30mer PS/PO AS ODN, the EWS gene expression was inhibited by 56% compared to untransfected cells. This inhibition was reduced to 7% in nontumour NIH/3T3 cells. In contrast, after transfection with AS siRNA, the reduction in EWS mRNA expression was higher 
Proliferation Assay
To determine the cellular proliferation, we proceeded to a MTT assay 24 hours after transfecting NIH/3T3 or EWSFli1 NIH/3T3 cells, with the oligonucleotides, Fig. (4) . There was no sequence-specific effect on the cellular growth neither with the 25mer PS AS ODN nor with the AS siRNA, since no difference was noted between the tumour and the parental cells after transfecting with the antisense agent or its respective control. On the contrary, after a transfection with the structured 30mer PS/PO AS ODN, the proliferation of EWS-Fli1 NIH/3T3 cells was significantly inhibited until 48% compared to the untransfected cells whereas the 30mer PS/PO CTL ODN had no significant effect on the cellular growth (only 10% inhibition of EWS-Fli1 NIH/3T3 growth).
This specific inhibition was not observed in NIH/3T3 cells since the proliferation of NIH/3T3 after transfection with structured 30mer PS/PO AS and 30mer PS/PO CTL ODN were 88% and 87% of untransfected cells, respectively.
ews-fli1 and ews Proteins Expression after Structured 30mer PS/PO AS ODN Treatment
24 hours after transfecting EWS-Fli1 NIH/3T3 cells with the structured 30mer PS/PO AS ODN, we controled the ewsfli1 and ews proteins expression by western-blot analysis. We obtained no variation of the ews expression but a 38% inhibition of the ews-fli1 protein expression in comparison with the untransfected cells, Fig. (5) .
Reorganization of Actin Fibres
To explore possible correlations between the inhibition of the EWS-Fli1 oncogene expression and cytoskeleton reorganization, we performed actin filament staining with phal- loidin-FITC on NIH/3T3 and EWS-Fli1 NIH/3T3 fibroblasts before and after three successive transfections with various ODNs or siRNAs. Parental NIH/3T3 fibroblasts exhibit a highly organised actin filament network comprised of numerous, thick fibres. On the contrary, the actin cytoskeleton is entirely disrupted in EWS-Fli1 NIH/3T3 cells, showing no distinct fibres at all; and actin remains diffusely distributed within the cytoplasm, Fig. (6a) . After transfecting tumour cells with 25mer PS AS or its control and with structured 30mer PS/PO AS or its control, the same diffuse staining was observed inside the cells, Fig. (6b and 6c) . In contrast, the transfection of EWS-Fli1 NIH/3T3 cells with AS siRNA involved a less distributed staining all over the cytoplasm and actin fibres formation, whereas the actin cytoskeleton remained totally disrupted with CTL siRNA, Fig. (6d) . It appears that treating tumour cells with AS siRNA resulted in morphological reversion: the actin cytoskeleton reorganization.
DISCUSSION
In this study, we compare three antisense agents which have been shown in several in vitro or in vivo experimental models to present some interesting potentialities to treat Ewing sarcoma [6, 9, 11] . To select the best agent among 25mer PS AS ODN, structured 30mer PS/PO AS ODN or AS siRNA, we used fibroblastic NIH/3T3 cell line which had been stably transfected with the human EWS-Fli1 oncogene. The advantage of this in vitro model of Ewing sarcoma is its own negative control: the non-tumour parental NIH/3T3 fibroblasts. The antisense agents were vectorised with cationic lipids. The concentrations of 200nM and 50nM were used for ODNs and siARNs, respectively. These concentrations were optimised to obtain similar levels of oncogene expression inhibition. Moreover this inhibition is the highest one with the lowest toxicity. The effects of these three antisense agents were studied according to three parameters: (a) the fluctuation of the oncogene and the EWS gene expressions, not only in tumour cells but also in parental NIH/3T3 fibroblasts, (b) the modification of tumour and non-tumour cell proliferation and finally (c) the reorganization of actin cytoskeleton.
We observed the stimulation of both the oncogene (after transfection with the CTL siRNA) and the EWS gene ex- pression (after transfection with the 30mer PS/PO CTL ODN, the 25mer PS AS ODN, or the CTL siRNA). The variation in expression of untargeted genes is unfortunately often described [22] [23] [24] [25] .
According to our findings, the 25mer PS AS ODN does not specifically inhibit the oncogene expression after 4 hours in comparison with the ODN CTL. Moreover, after 4 hours, the EWS gene expression was a 1.5-fold increased in tumour EWS-Fli1 cells compared to untransfected cells but not modified in parental NIH/3T3 fibroblasts (94% of untreated cells). The cellular growth inhibition was unspecific (both in term of cell type and ODN sequence). In our experimental conditions, the antisense activity of 25mer PS AS ODN may not be showed because of an unspecific intracellular penetration and traffic.
Like previous studies [14] , we confirm that the structured 30mer PS/PO AS ODN induced strong and almost specific inhibitions of EWS-Fli1 mRNA expression (measured by real-time Q-PCR) and cellular proliferation in tumour EWSFli1 NIH/3T3 cells (88% and 48% in comparison with untransfected cells, respectively). The 2'-O-methyl modified structured 30mer PO AS ODN inhibited the EWS-Fli1 mRNA expression as strongly as the unmodified ODN (87%). Therefore, the alkyl modification in the loop domain does not disrupt the antisense activity of the antisense agent. As 2'-O-methylation modification blocks RNase H cleavage of the target mRNA, we can assert that the loop is not mainly responsible of the inhibition of the oncogene expression. In consequence, to carry on its antisense effect, the structured 30mer PS/PO AS needs to be disorganised and to become linear.
The penetration of ODNs doesn't differ between the two cellular types (data not shown). Therefore, it is difficult to explain why EWS mRNA expression was more down regulated by the structured 30mer PS/PO AS ODN in tumour cells than in NIH/3T3 (respectively 44% and 93% of EWS mRNA level in untransfected cells). By contrast, the structured 30mer 2'OMe PO AS ODN did not modify the expression of EWS both in tumour and NIH/3T3 cells (respectively 93% and 101% of untransfected cells). Indeed, the 2'-Oalkyl modifications only concern bases directed against the EWS part of the junction point. Since they are known to inhibit the RNase H cleavage, the area of RNase H cut in the EWS part is reduced in comparison with the unmodified AS ODN. Then, the EWS gene is not down regulated [26] [27] [28] [29] . The consequences of inhibited EWS gene expression in nontumour cells are still unknown. For therapeutic purposes, it would be preferable to maintain EWS mRNA expression at its physiological level. So, finding almost no variation of EWS gene expression in normal NIH/3T3 cells after transfection with the structured 30mer PS/PO AS ODN is very valuable for its promising use in clinical trials.
In our in vitro Ewing sarcoma model, our results point out that the AS siRNA has two targets: not only the EWSFli1 oncogene but also the EWS gene. Indeed, in the tumour EWS-Fli1 NIH/3T3 cells where these two targets are present, the molecules of AS siRNA are distributed according to their affinity and the availability of the two targets (28% and 77% inhibitions of EWS and EWS-Fli1 expressions compared to untreated cells, respectively). But, in the nontumour NIH/3T3 fibroblasts, all the molecules of AS siRNA are free to inhibit just the remaining target, the EWS gene (inhibition of EWS expression at 85% compared to untransfected cells). It is important to notice that the sequence of the AS siRNA has more homology with the EWS part of EWSFli1 (15 nucleotides out of 19) than the Fli1 part. It is well known that siRNAs can tolerate one to several mismatches to the mRNA targets and that only a partial homology is sufficient for an effective silencing of untargeted protein [23] . On the contrary, with the same siRNA, Dohjima et al. found only 5% inhibition of EWS [9] . But the siRNA was intracellularly expressed and the housekeeping gene chosen to normalize the inhibitions was not the same. In a therapeutic point of view, the ability of siRNA to strongly inhibit EWS expression could represent a serious problem unless tumour cells specific transfection is guaranteed.
No inhibition of tumour cell proliferation occurred after AS siRNA treatment (cellular growth of 98.6% in comparison with the untreated cells). This is a very unexpected result if we consider that oncogene expression and cell growth inhibitions are reliable. Indeed, as previously illustrated in another Ewing sarcoma model [9] , we obtained 77% inhibition of oncogene mRNA expression after the transfection of EWS-Fli1 NIH/3T3 cells with AS siRNA. This down regulation was only 11% lower than the one mediated by structured 30mer PS/PO AS ODN with which the cellular proliferation is 48% inhibited. This difference seems too small to justify that no consequence with the AS siRNA was observed at the cellular proliferation level. On the contrary, in the same tumour cells, the inhibition of EWS mRNA expression mediated by AS siRNA was twice lower than the one induced by the structured 30mer PS/PO AS ODN (28% and 56% compared with untransfected cells, respectively). Spahn et al. showed that homo-and hetero-oligomerisation of ews and ews-fli1 proteins occurs [30] . However, their functional consequences remain to be elucidated. Accordingly, we first supposed that in tumour EWS-Fli1 NIH/3T3, the simultaneous downregulation of EWS-Fli1 and EWS by the structured 30mer PS/PO AS ODN might have a cooperative effect via consecutive down regulation at protein level. This hypothesis could explain why the inhibition of tumour cells proliferation only happened after the transfection with structured 30mer PS/PO AS ODN and not with AS siRNA. Several authors reported controversial conclusions regarding genesis of Ewing sarcoma family of tumors. Kovar et al. have shown that ews protein is dispensable for Ewing tumor growth. Some authors suppose that the heterodimerisation of ews-fli1 with ews proteins may be involved in the DNA-binding independent pathway of the Ewing's tumours genesis [30] [31] [32] [33] . So, we proceeded to the western-blot analysis 24 hours after transfecting EWS-Fli1 NIH/3T3 cells with structured 30mer PS/PO AS ODN. Consistent with the Q-PCR results, we detected 38% inhibition of ews-fli1 protein expression compared to untransfected cells. This inhibition is quite similar to which was obtained in the same conditions by Maksimenko et al. [14] . Unfortunately, no decrease of ews protein expression was quantified. We concluded that the effect observed on cellular proliferation after AS treatment is not due to the simultaneous down regulation of ews-fli1 and ews. No evidence was found about the role of the heterodimerisation of ews-fli1 with ews in the Ewing sarcoma pathogenesis. We had to notice that there is a correlation between RNA and protein down regulations for EWS-FLI1 but not for EWS. To explain this, we can suppose that ews-fli1 and ews proteins are differently regulated. The ews-fli1 turnover may be more rapid than ews one.
Finally, to explain why the structured 30mer PS/PO AS ODN inhibited the cellular growth and siRNA did not, while both down regulated the oncogene mRNA expression, we may find an explanation with microRNA (miRNA) and offtarget effect concepts. Indeed, it is now well known that transcripts needn't total complementarity with a siRNA to be targeted for knockdown by the RNAi pathway [23, [34] [35] [36] [37] [38] . Bioinformatic tools are more and more available on the web. Thanks to the miRBase database [39] , we identified sequence homologies between AS siRNA and two miRNAs: mmu-mir-883a-5p and mmu-mir-346 (respectively ten and seven bases in common). Even if it doesn't prove that the AS siRNA acts as a miRNA, doubts remain. And caution is especially necessary since mmu-mir-883a-5p and mmu-mir-346 possess a large number of target mRNA [39, 40] . The most annoying is the discovery of 14 murine genes of which the sequences partially match with the sense or the antisense AS siRNA strand [41, 42] . Among 19 bases of the siRNA strands, the number of mismatches varies from 2 to 4. But all present contiguous match part between 9 to 15 bases which might be enough for RNAi process. Therefore, it seems that the AS siRNA could possess a lot of off-target genes. One or several of them like Src (see [43] [44] [45] [46] for reviews) could act in cell growth. And, we hypothesize that we cannot observe a cellular proliferation effect mediated by AS siRNA because of those off-target genes that remain to be identified.
At last, cell transformation often involves changes in cell architecture, essentially linked to profound cytoskeleton rearrangements. In particular, in our in vitro model of Ewing sarcoma, the expression of EWS-Fli1 in NIH/3T3 fibroblasts induces the complete disruption of the actin fibres network [20, 21] . The reorganization of actin fibres cytoskeleton was only obtained after transfection with AS siRNA. This illustrates completely what Bertrand et al. showed: the effects of siRNAs are lasting for a longer time than the ones of AS ODN in cell culture [22] . In this way, we expect that structured 30mer AS ODN could also involve this phenotypic reversion if it is maintained intact for a longer time.
CONCLUSION
To conclude, we observe that according to its efficacy, its specificity and the absence of induced cell phenotypic rever-sion, the 25mer PS AS ODN does not present interesting enough features in our in vitro murine model of Ewing sarcoma. Our results confirm that structured 30mer PS/PO AS ODN and AS siRNA have both promising potentialities to design a new therapy directed against Ewing sarcoma. They highly inhibit EWS-Fli1 mRNA expression. AS siRNA causes an interesting effect on actin cytoskeleton reorganization. However we cannot exclude that it has also an action on off-target genes. To prevent undesired effects systems allowing either a direct expression of a shRNA in tumor cells or a tumor targeted vectorisation of siRNA should be developed. With a strong effect on cellular proliferation and no serious adverse effect detected, structured 30mer PS/PO AS ODN appears to be the best of the three tested antisense agents. It is efficient but needs a longer half-life through the improvement of its resistance to nuclease degradation. It is now necessary to design the best partner to protect and vectorise it inside the cells.
